Jump to content

Bococizumab: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m Added link to corresponding ligand page on the IUPHAR/BPS Guide to PHARMACOLOGY
Line 36: Line 36:
| PubChemSubstance = 194168554
| PubChemSubstance = 194168554
| DrugBank =
| DrugBank =
| IUPHAR_ligand = 7730
| ChEMBL = 3137349
| ChEMBL = 3137349
| ChemSpiderID = NA
| ChemSpiderID = NA

Revision as of 08:40, 2 July 2015

Bococizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetProprotein convertase subtilisin/kexin type 9 (PCSK9)
Clinical data
Routes of
administration
Subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem SID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC6414H9918N1722O2012S54
Molar mass145.1 kDa g·mol−1

Bococizumab[1] (RN316)[2] is a drug in development by Pfizer targeting PCSK9 to reduce LDL cholesterol.[3]

Description

Bococizumab is a monoclonal antibody that inhibits PCSK9, a protein that interferes with the removal of LDL. LDL levels are a major risk factor for cardiovascular disease.

Clinical trials

A phase 2b study of statin patients was presented at the 2014 American College of Cardiology. Monthly or bimonthly injections resulted in significantly reduced LDL-C at week 12.

The Phase 3 SPIRE trials plan to enroll 17,000 patients to measure cardiovascular risk. High risk and statin intolerant subjects will be included.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bococizumab" (PDF). American Medical Association.
  2. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  3. ^ "Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study". Retrieved 29 December 2014.